

February 7, 2007



## Rigel to Present at BIO CEO & Investor Conference 2007

SOUTH SAN FRANCISCO, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present at the BIO CEO & Investor Conference 2007 on Monday, February 12th at 1:15 p.m. EST. Mr. Gower is also scheduled to serve as a panelist in a therapeutic focus session titled "Autoimmune Disease - Life After TNF", which is taking place on Wednesday, February 14th at 9:00 a.m. EST. The conference will be held at the Waldorf Astoria Hotel in New York City.

To access the live audio webcast or the subsequent archived recording, log on to [www.rigel.com/rigel/events](http://www.rigel.com/rigel/events). Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel ([www.rigel.com](http://www.rigel.com))

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to file one new investigative new drug (IND) application in a significant indication each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue clinical development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2006. Rigel does not undertake any obligation to update forward-

looking statements.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: [invrel@rigel.com](mailto:invrel@rigel.com)

SOURCE Rigel Pharmaceuticals, Inc.